| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Quanterix Corporation$3.92
+0.1 (+2.6%)
Market Cap
126.72 M
EPS
-2.37
P/E Ratio
-
Value Trade
2.46 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
36.41 M
R&D Expenses
7.32 M
Operating CF
-18.11 M
Total Assets
366.67 M
Total Liabilities
84.53 M
Equity
282.14 M
D/E Ratio
12,345
-2.18 %
Week
-17.23 %
1 Month
-54.41 %
3 Month
-54.33 %
6 Month
-94.45 %
5 Year
-83.45 %
All Time
Cash Data
Cash Position
99.27 M
Monthly Burn
6.04 M
Runway
13.9 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
418.19 K
52 Week Range
2.40 - 8.77
% held by Insiders
12.29 %
% held by Institutions
73.32 %
Enterprise Value
62.79 M
Total Shares
47.08 M
Short %
10.47 %
Float Shares
43.08 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QTRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QTRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QTRXQuanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation has announced an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4). This action demonstrates the company's ongoing commitment to adhere to regulatory standards while potentially enhancing its attractiveness to investors.
Read more →QTRXAnthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
Quanterix Corporation announced significant milestones in the clinical adoption of its blood-based Alzheimer's testing, LucentAD® Complete. Anthem Blue Cross and Blue Shield has established commercial coverage for this innovative five-analyte ATN(I) algorithmic test, which aids clinicians in evaluating Alzheimer's disease. These developments highlight the increasing importance of blood-based assessments in Alzheimer's diagnostics.
Read more →QTRXQuanterix Announces Appointment of Jason Faessler as Chief Financial Officer
Quanterix has announced the appointment of Jason Faessler as Chief Financial Officer. This leadership change is part of the company's strategy to enhance its financial management. Further details about Faessler's background and the implications of this appointment were not provided.
Read more →QTRXQuanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Quanterix is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Details regarding the specific agenda or topics to be discussed at the conference have not been provided in the article. This participation highlights Quanterix's ongoing engagement in the healthcare sector.
Read more →QTRXQuanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The details of these grants were not elaborated upon in the article. This announcement is part of the company's compliance with Nasdaq regulations.
Read more →QTRXQuanterix Announces Planned Transition of Chief Financial Officer
Quanterix has announced a planned transition for its Chief Financial Officer. The details regarding the timing and the successor have not been disclosed in the announcement. This change is part of the company's ongoing leadership adjustments. Further information may be provided in upcoming communications.
Read more →QTRXLucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows
Lucent Diagnostics has partnered with Tempus AI to enhance Alzheimer's disease detection through a blood-based biomarker panel. This collaboration aims to integrate the testing into clinical workflows, leveraging AI technology to improve precision medicine. The initiative is expected to broaden access to this novel testing method, potentially benefiting early diagnosis and treatment.
Read more →QTRXQuanterix Releases Financial Results for the First Quarter of 2026
Quanterix has released its financial results for the first quarter of 2026. The article does not provide specific details regarding the financial performance or any significant developments. Further insights into the company's financial health and future outlook are not available in the provided text.
Read more →QTRXQuanterix To Report First Quarter 2026 Financial Results on May 6, 2026
Quanterix Corporation announced it will report its first quarter 2026 financial results on May 6, 2026. A conference call will be held at 4:30 p.m. E.T. to discuss these results. The company will issue a press release before the call and provide a live webcast for interested investors.
Read more →QTRXAidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
The article discusses the AidaBREAST™ multi-omic assay, which is designed for clinical oncology. However, it provides minimal information about the assay's performance or results. The content is primarily focused on privacy concerns, limiting the insights available to readers. Overall, the article does not convey significant positive developments regarding the assay.
Read more →QTRX▲ +6.2%on this newsshared move
Quanterix Debuts Content Innovation Engine at AACR 2026
Quanterix has introduced its Content Innovation Engine at the AACR 2026 event. This new technology aims to enhance content delivery and engagement within the biopharma sector. The specifics of the technology and its applications were not detailed in the article.
Read more →QTRXQuanterix Corporation Announces Date of 2026 Annual Meeting
Quanterix Corporation has announced that its 2026 annual meeting of shareholders will be held virtually on June 9, 2026. Shareholders of record as of April 14, 2026, will be eligible to vote. The company has also set a deadline of April 6, 2026, for shareholder proposals to be included in the proxy materials. This meeting marks an important engagement opportunity for stakeholders.
Read more →QTRX▼ -7.3%on this news· ran to -20% by day 3
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Quanterix Corporation reported strong financial results for Q4 and full year 2025, with revenues of $43.9 million and a cash balance of $122 million. The company aims to achieve cash flow breakeven in 2026, projecting revenues between $169 to $174 million. CEO Everett Cunningham expressed optimism about the company's growth and strategic direction following significant integration milestones.
Read more →QTRXLucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
Lucent Diagnostics has partnered with Life Line Screening to offer advanced blood-based diagnostics across the U.S. This initiative aims to provide non-invasive testing for chronic conditions, particularly Alzheimer's disease, in community settings. The collaboration seeks to promote early detection and informed treatment pathways, leveraging Life Line Screening's extensive outreach capabilities.
Read more →QTRX▲ +6.8%on this newsshared move
Quanterix to Participate in Upcoming Investor Conferences
Quanterix Corporation (QTRX) will participate in two investor conferences in March 2026. The events include the 46th Annual TD Cowen Healthcare Conference and the Leerink Global Healthcare Conference. The company's leadership will engage in fireside chats and one-on-one meetings, showcasing their advancements in biomarker detection and diagnostics.
Read more →QTRXQuanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
Quanterix Corporation will host a conference call on March 2, 2026, to discuss its fourth quarter and full year 2025 financial results. A press release will be issued prior to the call, and investors can access the live webcast through the company's website. Quanterix is recognized for its advancements in ultra-sensitive biomarker detection.
Read more →QTRXQuanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
Quanterix Corporation has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test aimed at detecting Alzheimer's disease. This test, which utilizes a five-analyte panel, aims to provide clearer diagnostic insights for patients with cognitive symptoms. The submission is backed by extensive clinical evidence and is part of Quanterix's strategy to establish its technology as a standard in clinical diagnostics.
Read more →QTRXQuanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling
Quanterix Corporation announced a landmark study published in JAMA Network Open, demonstrating that a multi-analyte approach combining biomarkers for amyloid, tau, neurodegeneration, and neuroinflammation offers superior insights into Alzheimer's disease progression. The study followed nearly 300 individuals for up to 15 years, revealing that this method significantly enhances clinical risk assessment. Quanterix's Simoa technology was pivotal in these findings, supporting the development of their LucentAD Complete test for amyloid pathology risk.
Read more →QTRX▼ -5.1%on this newsshared move
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Quanterix Corporation announced inducement grants to four new employees on January 15, 2026. The grants include 88,050 restricted stock units and options for 125,745 shares at an exercise price of $7.95. These grants are part of the company's 2025 Inducement Plan and were approved by the Compensation Committee. Quanterix continues to lead in ultra-sensitive biomarker detection.
Read more →QTRX▲ +23.8%on this news
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
Quanterix Corporation has appointed Everett Cunningham as its new President and CEO, effective January 19, 2026. Cunningham, who has a strong background in commercial leadership, will succeed Masoud Toloue, who will remain as an advisor. The company anticipates exceeding its revenue and cash guidance for 2025, positioning itself for growth.
Read more →QTRXQuanterix Appoints Everett Cunningham as President and CEO Effective
Quanterix Corporation has appointed Everett Cunningham as its new President and CEO, effective January 19, 2026. Cunningham will succeed Masoud Toloue, who will assist during the transition. The company anticipates exceeding its revenue and cash expectations for the complete year of 2025, reflecting strong growth prospects. Cunningham, previously Chief Commercial Officer at Illumina, brings significant industry experience, having held prominent roles in companies focused on diagnostics and healthcare. His appointment is expected to further advance Quanterix's mission in precision medicine and health outcomes.
Read more →QTRXQuanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence
Quanterix Corporation announced a landmark study published in Nature, which is the largest assessment of Alzheimer's Disease Neuropathological Changes (ADNC) to date. Conducted on over 11,000 individuals aged 58 and above, the study reveals a significant increase in ADNC prevalence with age. It provides crucial data for identifying asymptomatic individuals who may benefit from early intervention.
Read more →QTRXQuanterix Announces Board and Leadership Changes to Support Next Stage of Growth Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead I
Quanterix Corporation announced key leadership and board changes to bolster its growth phase. Garret Hampton and Alan Sachs have been appointed to the Board, both bringing extensive experience from Thermo Fisher Scientific. Bill Donnelly has transitioned from non-Executive Chair to Executive Chair, while Jeffrey Elliott has become the Lead Independent Director. The company aims to expand its biomarker detection capabilities, particularly with the recent Akoya acquisition, signaling a focused effort to enhance its diagnostic tools and market standing.
Read more →QTRXQuanterix Releases Financial Results for the Third Quarter of 2025
Quanterix Corporation announced its financial results for Q3 2025, reporting a revenue increase of 12.3% year-over-year to $40.2 million. Despite facing challenging market conditions, the company successfully integrated Akoya, achieving significant cost synergies. Quanterix's Alzheimer's diagnostics segment continues to grow, supported by a positive Medicare pricing recommendation and new partnerships in Asia. However, the reported adjusted EBITDA loss widened to $11.9 million, influenced by increased restructuring expenses and a decrease in gross margins.
Read more →QTRXQuanterix Releases Financial Results for the Second Quarter of 2025
Quanterix Corporation (NASDAQ QTRX) reported its financial results for the second quarter of 2025, revealing a revenue drop of 29% to $24.5 million compared to the previous year. Despite this decline, the company's Alzheimer's Diagnostics revenues more than tripled, and it has made significant advancements, including the successful acquisition of Akoya Biosciences. The CEO, Masoud Toloue, expressed optimism regarding the business's growth potential and indicated that the company is on track to achieve cash flow breakeven by 2026, even amidst challenging market conditions.
Read more →QTRXQuanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum
Quanterix Corporation has completed its acquisition of Akoya Biosciences, establishing an integrated platform for measuring biomarkers in neurology, oncology, and immunology. The transaction involves the issuance of approximately 7.8 million shares and a cash payment of around $20 million. With this merger, Quanterix anticipates expanding its addressable market significantly and achieving profitability by 2026. Management changes have also occurred, with new directors joining Quanterix's Board from Akoya, while two existing members have resigned.
Read more →QTRX▲ +8.5%on this news
Quanterix Releases Financial Results for the First Quarter of 2025
Quanterix Corporation reported its financial results for Q1 2025, which included a revenue of $30.3 million, a 5% decrease compared to the previous year. The company is undertaking cost reduction measures to save approximately $30 million annually amidst ongoing market challenges and aims for positive cash flow by 2026. Additionally, Quanterix announced new products like the Simoa ONE assay kits and saw significant partnerships with ARUP Laboratories for Alzheimer's testing. However, the net loss for the quarter increased to $20.5 million, compared to a net loss of $11.2 million in the prior year.
Read more →QTRXQuanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and
Quanterix Corporation and Akoya Biosciences have announced an amendment to their merger agreement, allowing Quanterix to issue approximately 7.76 million shares and provide $20 million in cash to Akoya shareholders. The revised terms mean Quanterix will issue over 9 million fewer shares compared to the original deal, leading to Quanterix shareholders retaining 84% ownership of the combined company. Both companies' leadership expressed strong confidence in the strategic merits and future value creation from the partnership, with the deal expected to close in the second quarter of 2025, pending shareholder approval and other customary conditions.
Read more →QTRXQuanterix Releases Financial Results for the Fourth Quarter of 2024 Delivers seventh consecutive quarter of double-digit revenue growth
Quanterix Corporation announced its financial results for the fourth quarter of 2024, reporting an 11% increase in revenue year-over-year. This period marks the company's seventh consecutive quarter of double-digit growth, ultimately reflecting resilience in a challenging market. The firm is moving forward with its acquisition of Akoya Biosciences, which aims to enhance its biomarker detection capabilities. However, Quanterix also reported a net loss of $11.6 million, an increase compared to the previous year, raising concerns about ongoing cash usage in the coming year.
Read more →QTRX▼ -5.9%on this news
Quanterix Provides Update on Financial Performance Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth
Quanterix Corporation reported preliminary financial results for Q4 and FY 2024, noting a revenue of $34.9 million in Q4 and $137.2 million for the fiscal year, marking a 12% growth year-over-year. CEO Masoud Toloue highlighted their seventh consecutive quarter of double-digit growth, attributing it to effective operational strategies despite market challenges. The company also announced a significant acquisition of Akoya Biosciences, aiming to foster additional growth opportunities going forward. However, the report indicated a decline in instruments revenue and highlighted cash usage in the previous year.
Read more →QTRX▼ -19.7%on this newsshared move
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers
Quanterix Corporation has announced its acquisition of Akoya Biosciences in an all-stock transaction aimed at creating an integrated solution for the detection of blood- and tissue-based protein biomarkers. The merger is expected to enhance Quanterix's market position in high-growth areas such as neurology, oncology, and immunology. Additionally, the combined entity anticipates generating approximately $40 million in annual cost synergies by the end of 2026, positioning it for positive cash flow generation. The acquisition is projected to close in the second quarter of 2025, pending shareholder approvals and regulatory conditions.
Read more →QTRX▼ -19.7%on this newsshared move
Operator Hello, and welcome to today's call to discuss Quanterix's acquisition of Akoya Biosciences. At this time, our participants have been placed in listen-only mode. The call will be open for your questions following
Quanterix announced its acquisition of Akoya Biosciences, aimed at creating a leader in the detection of protein biomarkers. This strategic move will combine strengths in blood and tissue-based testing, targeting high-growth markets like oncology and immunology. Quanterix leaders expect significant operational synergies and enhanced growth opportunities through this acquisition, which will also provide value for shareholders. The deal is anticipated to close in the second quarter of 2025 pending shareholder and regulatory approvals.
Read more →QTRXQuanterix Expands Capabilities with Strategic Acquisition of EMISSION Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business
Quanterix Corporation announces its acquisition of EMISSION iNC., aimed at enhancing its technology capabilities through vertical integration of proprietary bead technology. The deal, valued at $10 million with additional performance-related payments, is set to close in January 2025. This acquisition is intended to bolster Quanterix's upcoming Simoa platform and extend its commercial offerings to third-party OEM customers. The transaction is expected to positively impact revenue and gross margins by 2026.
Read more →QTRXDocument Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024 Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook
Quanterix Corporation announced preliminary financial results for Q3 2024, revealing a 13% revenue increase to $35.7 million, marking the sixth consecutive quarter of double-digit growth. The company reaffirmed its full year revenue outlook while also disclosing the need to restate previous financial statements due to certain errors. Additionally, Quanterix launched a new multi-marker test for Alzheimer's detection, demonstrating its commitment to advancing diagnostics in neurodegenerative diseases. However, the restatement process may cause delays in the filing of quarterly reports.
Read more →QTRXQuanterix Welcomes Ivana Magov evi -Liebisch, Ph.D., J.D. to Board of Directors
Quanterix Corporation has announced the appointment of Dr. Ivana Magov evi -Liebisch to its Board of Directors. Dr. Magov evi -Liebisch has over 25 years of experience in the biopharmaceutical industry, including significant roles at Vigil Neuroscience and Ipsen. Her expertise in research and development, intellectual property, and business strategy is expected to support Quanterix's expansion in clinical diagnostics and enhance its leadership in biomarker detection for neurodegenerative diseases. CEO Masoud Toloue expressed optimism about the transformative potential in neurology, emphasizing the vital role of Simoa technology in advancing drug efficacy monitoring.
Read more →QTRX▲ +7.7%on this news
Jeffrey Elliott Appointed to Quanterix's Board of Directors
Quanterix Corporation (NASDAQ: QTRX) has appointed Jeffrey Elliott to its Board of Directors. Elliott brings over 20 years of senior leadership experience in the medical diagnostics field, including significant roles at Exact Sciences Corp. where he excelled in scaling business operations. His expertise is seen as crucial in advancing Quanterix's goals, particularly in the development of infrastructure for Alzheimer's Disease testing. The company's leadership expresses enthusiasm about leveraging Elliott's experience to drive future growth and innovation.
Read more →QTRXQuanterix Releases Financial Results for the Second Quarter of 2024
Quanterix Corporation announced its financial results for Q2 2024, highlighting a 10.8% revenue increase to $34.4 million. Despite this growth, the company reported a net loss of $9.5 million, an increase from the previous year's loss. Significant operational milestones included successful testing for Alzheimer's disease detection and new partnerships with major hospital systems. The company adjusted its revenue guidance for the year due to a constrained capital funding environment.
Read more →QTRXQuanterix Releases Financial Results for the First Quarter of 2024 BILLERICA, Mass. - May 7 , 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection
Quanterix Corporation announced its financial results for the first quarter of 2024, revealing a focus on innovation in biomarker detection. The company expects total revenue between $139 to $144 million for the year, while reporting a net loss of $10,072. The CEO highlighted the launch of new assays aimed at improving the measurement of Tau and enhancing the early detection of neuro-pathologies. Despite increasing operating expenses and a higher net loss compared to the previous year, Quanterix maintains a strong outlook for its research-only business.
Read more →QTRXQuanterix Releases Operating Results for Fourth Quarter and Full Year 2023 BILLERICA, Mass. - February 29 , 2023 - Quanterix Corporation (NASDAQ : QTRX), a company fueling scientific discovery through ultrasensitive biom
Quanterix Corporation announced its financial performance for Q4 2023 and the full year, showcasing strong growth in revenue and a successful corporate transformation. The company reported a net loss of $12.4 million for the quarter; however, this reflects an improvement from the prior year. Looking ahead, management projects 2024 revenue between $139 to $144 million, primarily from their research business. Quanterix also highlighted progress in their diagnostics efforts aimed at Alzheimer's disease, signaling a positive outlook for future growth.
Read more →QTRXQuanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
Quanterix Corporation has announced the rescheduling of its Q4 and full year 2023 earnings conference call to February 29, 2024, to align with the deadline for filing its Annual Report on Form 10-K. The company reaffirms its earlier guidance regarding revenue, gross margin, and cash usage for the year. An accompanying press release will precede the conference call, with options for investors to join via a webcast. The announcement emphasizes proactive communication and transparency around its financial performance.
Read more →QTRX▼ -9.1%on this news
Create the tools enabling discovery and better health O U R M I S S I O N 1 1. Preliminary unaudited full year results for 2023.​ 2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the
QTRX has released preliminary unaudited full-year results for 2023, projecting a GAAP gross margin percentage in the high 50s and a non-GAAP gross margin of around 50%. Significant operational improvements have been noted, including a reduction in cash burn by over three times and an increase in manufacturing capacity to over 4 million tests annually. The company also reported a strong balance sheet with more than $300 million in net cash, indicating financial stability and growth potential.
Read more →QTRXQuanterix Releases Operating Results for Third Quarter 2023
Quanterix Corporation has reported its financial results for the third quarter of 2023, highlighting progress in its strategic transformation plan aimed at scalability and innovation. The company's revenue expectations for the full year were raised to between $118 and $120 million, reflecting solid product and service revenue growth. Additionally, Quanterix has launched a key Alzheimer's test, bolstering its market position. However, the company also faced a significant net loss, indicating ongoing challenges in managing operational costs.
Read more →QTRXWilliam P. Donnelly Appointed to Quanterix's Board of Directors Billerica, Mass.
Quanterix Corporation (NASDAQ: QTRX) has appointed William P. Donnelly to its Board of Directors. With over 21 years of experience in the life sciences tools sector, Donnelly previously held senior roles at Mettler-Toledo International Inc. and is expected to add considerable value as Quanterix expands its infrastructure for Alzheimer's diagnostic support. Both Donnelly and Quanterix's CEO expressed excitement about the company's potential for growth and innovation in blood biomarker technology.
Read more →QTRXQuanterix Appoints Vandana Sriram as Chief Financial Officer Billerica, Mass.
Quanterix Corporation has appointed Vandana Sriram as Chief Financial Officer, effective August 21, 2023, succeeding Michael Doyle. Sriram, with over 20 years of experience in financial leadership, has a strong background in supporting high-tech manufacturing industries. Her previous roles include Senior Vice President of Global Finance at Azenta Life Sciences and key positions at GE Aviation. The CEO expressed confidence in Sriram's ability to enhance Quanterix's strategic growth initiatives as the company continues its corporate transformation.
Read more →QTRX▼ -5%on this newsshared move
Quanterix Releases Operating Results for Second Quarter 2023
Quanterix Corporation has announced its financial results for the second quarter of 2023, highlighting significant progress in its corporate transformation. The company achieved cash flow break-even and increased its full-year revenue expectations to between $110 million and $116 million, signaling positive growth. Despite these achievements, Quanterix reported a net loss of $6.064 million for the quarter, alongside high operating expenses which continue to weigh on profitability. The company remains focused on advancing its Simoa platform, integral to neurological disease diagnostics.
Read more →QTRXQuanterix Releases Operating Results for First Quarter 2023
Quanterix Corporation released its financial results for the first quarter of 2023, reporting a reduction in revenue and a net loss of $6,103 compared to $18,153 in the same period last year. The company remains optimistic about its corporate transformation and a modest revenue increase for the full year. Furthermore, Quanterix sees potential for growth due to the FDA's approval of tofersen, which highlights the importance of biomarkers in neurodegenerative diseases.
Read more →QTRX▲ +12.1%on this news
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations Corporate Transformation
Quanterix Corporation (NASDAQ: QTRX) reported its fourth quarter and full year 2022 financial results, which were in line with expectations as the company continues its corporate transformation. The CEO highlighted good progress in their strategic realignment and improvements in gross margins quarter over quarter. Despite this, the company faced a GAAP operating loss of $22.3 million, influenced by restructuring and impairment costs. The webcast for the earnings call provides additional insights into their future directions.
Read more →QTRXQuanterix Announces Appointment of Brian Blaser to Board of Directors Billerica, Mass.
Quanterix Corporation has appointed Brian Blaser to its Board of Directors effective January 6, 2023. With over 25 years of leadership experience in the in-vitro diagnostics industry, Blaser has previously worked at Abbott Laboratories and most recently served as a Senior Advisor to McKinsey. His experience is expected to bolster Quanterix's strategic initiatives as the company continues to expand its diagnostics capabilities. Blaser expressed enthusiasm for working with diverse teams to drive performance and growth.
Read more →QTRXQuanterix Corporation Releases Operating Results for Third Quarter 2022 Billerica, Mass.
Quanterix Corporation Releases Operating Results for Third Quarter 2022 Billerica, Mass. - November 8, 2022 - Quanterix Corporation (NASDAQ: QTRX), a company driving scientific discovery through ultrasensitive biomarker detection, today announced operating results for the thr
Read more →QTRX▼ -5.6%on this news· ran to -57% by day 1
Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance Billerica, Mass.
Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance Mass. - August 8, 2022 - Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker d
Read more →QTRXQuanterix Announces Appointment of Karen A. Flynn to Board of Directors
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors BILLERICA, Mass. - June 6, 2022 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Fl
Read more →QTRX▼ -9.1%on this news
Quanterix Corporation Releases Operating Results for First Quarter 2022 Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research Billerica, Mass.
Quanterix Corporation Releases Operating Results for First Quarter 2022 Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research Billerica, Mass. - May 10, 2022 - Quanterix Corporation (NASDAQ: QTRX), a company digiti
Read more →QTRX▼ -6.3%on this news
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021 Company strengthens balance sheet ending FY with GAAP total revenue growth increase of 28% led by strong performance in neuro-related
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021 Company strengthens balance sheet ending FY with GAAP total revenue growth increase of 28% led by strong performance in neuro-related studies and applications Executive leadership successio
Read more →QTRXQuanterix Provides Operational and Preliminary Financial Highlights Expects Q4 2021 revenue of $29-31 million; Full year 2021 revenue of $109-111 million Q4 Product & Service revenue of $28-30 million, 35% growth; Full y
Quanterix Provides Operational and Preliminary Financial Highlights Expects Q4 2021 revenue of $29-31 million; Full year 2021 revenue of $109-111 million Q4 Product & Service revenue of $28-30 million, 35% growth; Full year 2021 Product & Service revenue of $104-106 million
Read more →QTRXQuanterix Corporation Releases Operating Results for Third Quarter of 2021 Third quarter revenue driven by unprecedented growth in consumables (+98% vs PY) and instruments (+44% vs PY) Billerica, Mass.
Quanterix Corporation Releases Operating Results for Third Quarter of 2021 Third quarter revenue driven by unprecedented growth in consumables (+98% vs PY) and instruments (+44% vs PY) Mass. - November 4, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing bioma
Read more →QTRXQuanterix Corporation Releases Operating Results for Second Quarter of 2021 Q2 GAAP revenue including Grant Revenue $25.4M; Q2 Non-GAAP revenue $24.4M, an increase of 86% over prior year; instrument placements up 71% Bil
Quanterix Corporation Releases Operating Results for Second Quarter of 2021 Q2 GAAP revenue including Grant Revenue $25.4M; Q2 Non-GAAP revenue $24.4M, an increase of 86% over prior year; instrument placements up 71% Mass. - August 5, 2021 - Quanterix Corporation (NASDAQ: QT
Read more →QTRXQuanterix Appoints Michael Doyle as Chief Financial Officer Doyle brings strong financial experience and track record to Quanterix Billerica, Mass.
Quanterix Appoints Michael Doyle as Chief Financial Doyle brings strong financial experience and track record to Quanterix Mass. - June 28, 2021 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision he
Read more →QTRXQuanterix Appoints Masoud Toloue as President of Quanterix and Diagnostics Toloue brings deep expertise and industry acumen to lead the Company's strategic expansion into diagnostics Billerica, Mass.
Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnostics Toloue brings deep expertise and industry acumen to lead the Company's strategic expansion into diagnostics Billerica, Mass. - May 11, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company helping to
Read more →QTRXQuanterix Corporation Releases Operating Results for First Quarter 2021 Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year Billerica, Mass.
Quanterix Corporation Releases Operating Results for First Quarter 2021 Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year Mass. - May 5, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company helping to transform
Read more →QTRXQuanterix Appoints Laurie Olson to Board of Directors Pharmaceutical veteran adds deep expertise in commercial and corporate strategy Billerica, Mass.
Quanterix Appoints Laurie Olson to Board of Pharmaceutical veteran adds deep expertise in commercial and corporate strategy Billerica, Mass. - April 28, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science
Read more →QTRXQuanterix Announces Appointment of Interim Chief Financial Officer Billerica, Mass.
Appointment of Interim Chief Financial Officer Billerica, Mass. - April 21, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has appointed Shawn Stetson as t
Read more →QTRXQuanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020 Q4 GAAP revenue including Grant Revenue $26.1M; Q4 non-GAAP revenue $21.6M, an increase of 36% versus prior year Billerica, Mass.
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020 Q4 GAAP revenue including Grant Revenue $26.1M; Q4 non-GAAP revenue $21.6M, an increase of 36% versus prior year Mass. - March 2, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company dig
Read more →QTRXQuanterix Prices Public Offering of Common Stock BILLERICA, Mass. (BUSINESS WIRE)
Quanterix Prices Public Offering of Common BILLERICA, Mass. (BUSINESS WIRE) - February 4, 2021 - Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced un
Read more →QTRXQuanterix Provides Operational and Preliminary Financial Highlights Expects Q4 2020 GAAP revenue of $24-26 million; Non-GAAP revenue of $20-22 million, up approximately 32% over prior Q4 Quanterix to present at J.P. Morg
Quanterix Provides Operational and Preliminary Financial Highlights Expects Q4 2020 GAAP revenue of $24-26 million; Non-GAAP revenue of $20-22 million, up approximately 32% over prior Q4 Quanterix to present at J.P. Morgan Healthcare Conference on January 13, 2021 at 3:40 pm
Read more →QTRXQuanterix Appoints William Geist as Chief Operating Officer Geist brings operational experience to Quanterix as the company scales to support rapid growth and commercial success Billerica, Mass.
Quanterix Appoints William Geist as Chief Operating Officer brings operational experience to Quanterix as the company scales to support rapid growth and commercial success Billerica, Mass. - November 18, 2020 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomark
Read more →QTRXQuanterix Corporation Releases Operating Results for Third Quarter 2020 GAAP revenue including one-time License and Grant revenue $31.4M; Non-GAAP revenue $18.3M, an increase of 22% versus prior year Billerica, Mass.
Quanterix Corporation Releases Operating Results for Third Quarter 2020 GAAP revenue including one-time License and Grant revenue $31.4M; Non-GAAP revenue $18.3M, an increase of 22% versus prior year Billerica, Mass. - November 5, 2020 - Quanterix Corporation (NASDAQ: QTRX),
Read more →QTRXQuanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics Billerica, Mass.
Quanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics Billerica, Mass. - October 5, 2020 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the s
Read more →QTRXQuanterix Announces Closing of Public Offering Including Exercise in Full of Underwriters' Option to Purchase Additional Shares BILLERICA, Mass. (BUSINESS WIRE)
Quanterix Announces Closing of Public Including Exercise in Full of Underwriters' to Purchase Additional Shares BILLERICA, Mass. (BUSINESS WIRE) - August 11, 2020- Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precisio
Read more →QTRXQuanterix Corporation Releases Operating Results for Second Quarter 2020 1H revenue up 12% versus prior year; Q2 services up 33% Billerica, Mass.
Quanterix Corporation Releases Operating Results for Second Quarter 2020 1H revenue up 12% versus prior year; Q2 services up 33% Billerica, Mass. - August 4, 2020 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precisi
Read more →QTRXQuanterix Corporation Releases Operating Results for First Quarter 2020 $15.7M revenues, 27% Q1 YOY revenue growth Billerica, Mass.
Quanterix Corporation Releases Operating Results for First Quarter 2020 $15.7M revenues, 27% Q1 YOY Mass. - May 5, 2019 - Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results
Read more →QTRXQuanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2019 46% Q4 revenue growth; 51% full year growth Billerica, Mass.
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2019 46% Q4 revenue growth; 51% full year growth Mass. - March 9, 2020 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health,
Read more →QTRXJ.P. Morgan Healthcare Conference |
J.P. Morgan Healthcare Conference | January 15, 2020 | 1 Compelling and Rare Investment Thesis EXECUTION Short - term to Mid - term: 2 - 3x Low Risk Research Value Creation x Adoption pace; $0 to $57M in 5 yrs x Technology and application validation x Low regulatory or reimbursem
Read more →QTRXQuanterix Corporation Releases Operating Results for Third Quarter 2019 Strong revenue growth and successful early launch of new HD-X Analyzer Billerica, Mass.
Quanterix Corporation Releases Operating Results for Third Quarter 2019 Strong revenue growth and successful early launch of new HD-X Analyzer Billerica, Mass. November 6, 2019 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science
Read more →QTRXQuanterix Prices Public Offering of Common Stock
Quanterix Prices Public Offering of Common Stock BILLERICA, Mass., August 9, 2019 (BUSINESS WIRE) Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previous
Read more →QTRXQuanterix Corporation Releases Operating Results for Second Quarter 2019 $13.5M revenues, 57% Q2 YOY revenue growth and 520 bps of gross margin increase Billerica, Mass.
Quanterix Corporation Releases Operating Results for Second Quarter 2019 $13.5M revenues, 57% Q2 YOY revenue growth and 520 bps of gross margin increase Billerica, Mass. August 6, 2019 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the
Read more →QTRXSarah Hlavinka Elected to Quanterix Board of Directors Adds broad-based experience growing and scaling multi-billion-dollar international companies Billerica, Mass.
Sarah Hlavinka Elected to Quanterix Board of Directors Adds broad-based experience growing and scaling multi-billion-dollar international companies Billerica, Mass. July 26, 2019 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advan
Read more →QTRXQuanterix Announces Agreement to Acquire UmanDiagnostics, World s Leading Neurofilament Light (Nf-L) Antibody Supplier Positions Quanterix to capitalize on significant growth opportunities with Nf-L applications in Alzhe
Quanterix Announces Agreement to Acquire UmanDiagnostics, World s Leading Neurofilament Light (Nf-L) Antibody Supplier Positions Quanterix to capitalize on significant growth opportunities with Nf-L applications in Alzheimer s Disease, Multiple Sclerosis, and other neurodegenera
Read more →QTRXQuanterix Raises $49.7 million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention Chairman and CEO Kevin Hrusovsky to present at BIO and provide details about the HD-X lau
Quanterix Raises $49.7 million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention Chairman and CEO Kevin Hrusovsky to present at BIO and provide details about the HD-X launch and vision for continuing to pioneer disruption in heal
Read more →QTRXQuanterix Corporation Releases Operating Results for First Quarter 2019 64% Q1 revenue growth and 650 bps gross margin improvement Lexington, Mass.
Quanterix Corporation Releases Operating Results for First Quarter 2019 64% Q1 revenue growth and 650 bps gross margin improvement Lexington, Mass. May 9, 2019 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision healt
Read more →QTRXAMENDMENT NO. 7 TO LOAN AND SECURITY AGREEMENT This AMENDMENT NO. 7 TO LOAN AND SECURITY AGREEMENT (this Amendment ), is entered into as of
AMENDMENT NO. 7 TO LOAN AND SECURITY AGREEMENT This AMENDMENT NO. 7 TO LOAN AND SECURITY AGREEMENT (this Amendment ), is entered into as of April 15, 2019, by and among (a) QUANTERIX CORPORATION, a Delaware corporation ( Borrower ), (b) the several banks and other financial inst
Read more →QTRXQuanterix Appoints Amol Chaubal as Chief Financial Officer Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth
Quanterix Appoints Amol Chaubal as Chief Financial Officer Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth LEXINGTON, Mass. March 28, 2019 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarke
Read more →QTRXQuanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2018 65% Q4 revenue growth; 65% full year growth Lexington, Mass.
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2018 65% Q4 revenue growth; 65% full year growth Lexington, Mass. March 7, 2019 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision hea
Read more →QTRXQuanterix Corporation Releases Operating Results for Third Quarter 2018 85% revenue growth Reclaimed unrestricted IVD rights Lexington, Mass.
Quanterix Corporation Releases Operating Results for Third Quarter 2018 Reclaimed unrestricted IVD rights Lexington, Mass. November 1, 2018 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced f
Read more →QTRXLEASE AGREEMENT BETWEEN SSI 900 MIDDLESEX MA LP, as Landlord AND QUANTERIX CORPORATION, as Tenant WITH RESPECT TO 900 MIDDLESEX TURNPIKE, BUILDING 1 BILLERICA, MASSACHUSETTS
SSI 900 MIDDLESEX MA LP, as Landlord QUANTERIX CORPORATION, as Tenant 900 MIDDLESEX TURNPIKE, BUILDING 1 BILLERICA, MASSACHUSETTS Page Article I TERM REFERENCE DATA 1 1.1. SUBJECTS REFERRED TO 1 1.2. EXHIBITS 4 1.3. SECURITY DEPOSIT 4 Article II PREMISES AND TERM 5 2.1. PRE
Read more →QTRXQuanterix Corporation Releases Operating Results for Second Quarter 2018 66% revenue growth Integration of Aushon in process Lexington, Mass.
Quanterix Corporation Releases Operating Results for Second Quarter 2018 Integration of Aushon in process Lexington, Mass. August 8, 2018 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced fin
Read more →QTRXQuanterix Corporation Releases Operating Results for First Quarter 2018 41% revenue growth First full quarter of SR-X sales Integration of Aushon in process Lexington, Mass.
Quanterix Corporation Releases Operating Results for First Quarter 2018 First full quarter of SR-X sales Integration of Aushon in process Lexington, Mass. May 9, 2018 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precisi
Read more →QTRXQuanterix Corporation Releases Operating Results for Fourth Quarter and Fiscal Year 2017 Revenue at high-end of range previously provided Successful IPO completed in December 2017 Launch of SR-X in Q4, earlier than plann
Quanterix Corporation Releases Operating Results for Fourth Quarter and Fiscal Year 2017 Lexington, Mass. March 14, 2018 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported financial results for the fo
Read more →QTRXRapid Growth with Compelling Consumable Pull-through Three-year Growth ($ in millions) Grew from 0 instruments Jan 14 (cumulative) 2018 Milestones Q1: Launch SR-X benchtop Q4: Launch HD-X: Trade in Expand menu by 30+ ass
Rapid Growth with Compelling Consumable Pull-through Three-year Growth ($ in millions) Grew from 0 instruments Jan 14 (cumulative) 2018 Milestones Q1: Launch SR-X benchtop Q4: Launch HD-X: Trade in Expand menu by 30+ assays Multiplexing, cost and sensitivity Globalize and enter P
Read more →QTRXQuanterix Corporation Announces Closing of Initial Public Offering
Quanterix Corporation Announces Closing of Initial Public Offering LEXINGTON, Mass. December 11, 2017 Quanterix Corporation, a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the closing of its initial public offer
Read more →Competitive Position
How QTRX ranks across every disease it competes inCompetitive Position is a premium feature
See how QTRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial